Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

Fig. 4

Overall survival analysis of rPDAC patients who received *peri-operative chemotherapy compared to no peri-operative therapy. The median OS for patients who received peri-operative chemotherapy (broken line) was 8 months and 5 months for those who did not receive perioperative chemotherapy (solid line). Log—rank p < 0.2206. *perioperative (both adjuvant and neoadjuvant therapy)

Back to article page